Bevacizumab, a humanized monoclonal antibody against VEGFA, has been approved by the US Food and Drug Administration agency for use in the treatment of glioblastomas, especially for patients experiencing tumor recurrence following the standard Stupp regimen44,45. The gene discussed is VEGFA; the disease is glioblastoma.